Marianne Pavel

A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial

R. Salazar, R. Riechelmann, E. Van Cutsem, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

G. Canaud, M. Caplin, E. Wolin, 2014 .

[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study.

T. Halfdanarson, P. Aimone, C. Yoo, 2024, Journal of Clinical Oncology.

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

T. Halfdanarson, P. Aimone, Stephen Falk, 2024, The Lancet.